My first question is on the Asia business. We have seen softness due to softer traction in certain markets. So could you name the markets where we are seeing softer traction?
Okay. So could you just give us a guidance like for FY '26, what are we guiding for full year for Asia branded and Africa branded?
Yes. So, my first question is, since we are talking about entering new therapies even in Asia and Africa market, so do we want to increase our growth guidance in next 2 to 3 years? Similarly, even for the Indian market, since now we are entering newer therapies, so should we still look at 12% to 15% growth? Or can we look at higher growth because of these newer therapy?
Yes, my second question is now on the similar line. So , because we are talking about these businesses becoming bigger eventually. So , can we expect 30% kind of EBITDA margin and above, because of these new therapies scaling out maybe from '27 and beyond?
Congratulations on the good set of numbers. My first question is on the Novo Nordisk deal that we have announced yesterday. I see that we are the exclusive distributor on this Novo Nordisk thing, semaglutide. So how big do we see this opportu nity to be? Can it be bigger than the Sanofi's in-licensed portfolio? Some color that if you can just share, how big do you see this opportunity?
Yes. That's helpful. But I was just looking out like in a chronology if we have to do it. Like Sanofi's in -license portfolio would be around INR 200 crores for us. So do you expect this opportunity to be bigger than the Sanofi's opportunity?
Thank you for the opportunity. My question is on the European market. So , ex of NRT, the European market has grown at 22%. So, how sustainable is this growth rate going forward? And if you could explain the reason for this kind of growth?
Thank you for the opportunity. Our emerging markets growth is quite buoyant in this quarter. So, I hear that it was led by both generics as well as innovative products. But can we elaborate more on this and give us some direction, like going forward how should we look at this region?
Okay. My second question is a little open-ended and it is on the India business GLP opportunity. So, given that the market is going to be very crowded, so what are our thoughts, I mean, how excited are we to be in this competitive market?